2023年2月22日

VCPro数据库2023 26日版-一个可下载的和可搜索的数据库与风险资本6900 +全球风险资本和私人股本公司。最可靠的、最新的和负担得起的风险资本的目录。VCPro数据库可以在Windows和macOS版本。自1998年以来,它已经出版。医学技术公司目前外科提出了320万美元的种子轮由真实的企业新智能手术针和software-enabled手术平台允许更大的精度和范围的治疗治疗华盛顿2月21日2023——目前外科公司今天宣布了一项320万美元的种子资金轮由真正的企业,从1517年开始参与基金和SciFounders。总部位于华盛顿特区的医学技术公司正在开发一种software-enabled手术平台准确地允许医生和治疗治疗一系列的疾病。因为合伙人Alireza (Al) Mashal博士和克里斯·瓦格纳博士,2020年开始目前的手术,公司总共筹集了400万美元,其中包括小企业创新研究从美国国家科学基金会的资助。癌症仍然是主要的死亡原因在全世界范围内,每年有超过1800万新病例检测。50%以上的这些情况现在发现在早期阶段,然而治疗选项并没有跟上步伐。例如,唯一的实体肿瘤的治疗选择是一个外科手术。 However, nearly 50% of patients are not eligible for surgery, because the tumor is too difficult to remove without damaging surrounding organs. Chemotherapy and radiation therapies, with their associated side effects, therefore remain the most common treatment options, which are non-curative for most cancers. Current Surgical is addressing this lack of curative treatment by giving doctors a precision guided needle that can accurately destroy tumors, without harming surrounding healthy tissue, anywhere in the body. Current Surgical's smart surgical needle technology combines high resolution sensors and real-time image analysis into one tool, giving doctors precise control and feedback while destroying tumors. As a result, surgeons will be able to treat any solid tumor in any location — allowing millions of patients to receive curative surgery without the traditional limitations. "Technological advancements now allow us to detect cancers earlier and earlier, but the capability to treat those tumors hasn't improved," explains Current Surgical CEO Al Mashal. "We are bridging this gap through our smart needle technology. We want to give doctors the ability to curatively treat cancers in hard-to-reach places — without the harmful, debilitating side effects of other treatment options." "We're excited about this technology not only for its curative potential, but also because of how easy it is to put into the hands of the surgeon," says Current Surgical CTO Chris Wagner. "Since the technology is integrated into the needle, it doesn't take a large, expensive operating room to actually help patients." "There's so much to be excited about with Current Surgical," said Natasha Sharma, principal at True Ventures. "Al and Chris have put their energy and deep experience with surgical robotics and biophysics into creating smart surgical needles that give surgeons 'eyes inside' so they can work with greater precision, like never before. This team also has immense compassion for the patients and customers who will benefit. We seek that in founders, and we can't wait to see this work come to life." Current Surgical's technology is automating key steps of surgery so doctors can instead focus on determining the best treatment for patients. Beyond treating even the most intractable diseases, the technology has wide-ranging applications, from treating cardiac arrhythmias and hypertension to other sources of chronic pain. About Current Surgical Current Surgical is a preclinical-stage company enabling a new generation of hybrid therapies through the development of smart surgical tools to allow doctors to precisely treat currently untreatable solid tumors. For more on Current Surgical, please visit www.currentsurgical.com and follow along on LinkedIn and Twitter @CurrentSurgical. About True Ventures Founded in 2005, True Ventures is a Silicon Valley-based venture capital firm that invests in early stage technology startups. With more than $3.8 billion under management, True provides seed and Series A financing to founders in some of today's fastest growing markets. To date, True has helped more than 350 companies launch and scale their businesses, creating over 85,000 jobs worldwide. To learn more, visit www.trueventures.com.